Johnson & Johnson is betting big on America, praising Trump’s investment tax policies
Johnson & Johnson Chairman and CEO Joaquin Duato joins ‘Mornings with Maria’ to provide insight into the US manufacturing system, advances in cancer treatment and the future of medical innovation.
Johnson & Johnson is betting big on America, crediting Trump’s tax policies, top talent and a strong investment climate to fuel a $55 billion US investment campaign that highlights growing confidence in US industry.
“We have the best talent, we have the best investment climate and, most importantly, we now have a tax policy in place with these managers that has helped us compete,” CEO Joaquin Duato said on FOX Business’ “Mornings with Maria” on Tuesday.
“We are playing with our hand tied behind our back when compared to the companies that were under the US”
“Now we can create high-skilled jobs, we can invest in America, and we can compete,” he added.
MEDICAL DEVICE GIANT HITS GLOBAL NETWORK DISRUPTION AFTER CYBERATTACK POSSIBLY LINKED TO PRO-IRANIAN GROUP
Joaquin Duato, chairman and CEO of Johnson & Johnson, speaks at the Punchbowl News Conference at Union Station on March 10 in Washington, DC. (Photos by Heather Diehl / Getty Images)
Duato told “Mornings With Maria” that the company’s goal is to make all of its drugs, medical technology and more in the US, citing the move as “a show of confidence in American industry.”
Johnson & Johnson’s latest efforts include an investment of more than $1 billion in the US Vision manufacturing facility in Jacksonville, Florida.
When discussing such investments, Duato emphasized Johnson & Johnson’s role in medical technology and pharmaceuticals, separating those businesses from the company’s former consumer health division.
REPUBLICANS SUBPOENA PFIZER EXEC DURING TESTING OF THE COVID VACCINATION ACT
Johnson & Johnson, an American multinational medical, pharmaceutical and perfumery company, is headquartered in Jan. 28, 2025 in Madrid, Spain. (Cristina Arias/Cover/Getty Images)
“Now we are focused on science and innovation. So what is our goal now? Our goal is to continue to deliver continuous growth through patient success,” he said.
Duato pointed to a newly approved drug called Icotyde, a once-a-day oral treatment for psoriasis and psoriatic arthritis that is designed to be effective and safe against injectable biologics.
He said the development “will revolutionize … autoimmune diseases.”
GET FOX BUSINESS ON THE GO BY CLICKING HERE
Fox News senior medical analyst Dr. Marc Siegel explains how AI technology is useful in medical care, ‘co-driver’ and more in ‘The Bottom Line.’
On the medical technology side, the company is seeking approval for its first robotic surgery system, which aims to improve surgical outcomes by assisting surgeons.
“We are not a trick horse company. We are a company with a stable of spoilers,” he said.
“We have 28 platforms at Johnson & Johnson over 1 billion, so that gives us the confidence to be bold enough to say that we have a vision of double-digit growth for Johnson & Johnson by the end of the decade, and that’s amazing for a company over 100 billion.”
